Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
STOP-IT: Feasibility of PPI Withdrawal in IBD
NCT07691138Phase 4Recruiting
- Sponsor
- University of Nottingham
- Start
- Jul 2026
- Primary completion
- Jul 2027
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial in inflammatory bowel disease (IBD) (2 arms), sponsored by University of Nottingham. Primary endpoints: Eligibility rate at 12 months, Recruitment rate at 12 months and 2 more. Started Jul 2026; status: recruiting.
02
Conditions
inflammatory bowel disease (IBD)
Beyond the preview
Go deeper on NCT07691138.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07691138.